Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
Teacher Yasmin Jeevanjee tells her story as a care partner in Kenya.
A paper published in the journal Brain has identified a brain disorder, known as LATE, which appears to mimic the clinical features of Alzheimer’s disease.
A message from ADI as 2018 comes to a close and what we look forward to in 2019.
Her Majesty Queen Silvia of Sweden has become an Honorary Ambassador of Alzheimer’s Disease International (ADI), in recognition of her personal commitment to work surrounding elderly and end of life care, and specifically dementia. Queen Silvia has a long-standing association with and in support of dementia. In 1996, she initiated…
Featured in the World Alzheimer Report 2018: The state of the art of dementia research: New frontiers, is Dr Jennifer Butte, a formal General Practitioner (GP) diagnosed with dementia. This is her story in her own words.
On World Alzheimer's Day, a doctor who diagnosed her own dementia after being misdiagnosed by her neurologist, is calling for an urgent response to dementia research and diagnosis.
In partnership with ITN Productions, ADI has released the documentary film ‘Every 3 seconds’ to help raise awareness on the global impact of dementia.
The World Health Organization (WHO) has published new materials around the Global action plan on dementia, produced in partnership with ADI.